Table 7 LASSO Regression

Age at Onset

1

VEGFA

chr6

0.14

7.36

1.61

9.17E-05

Age at Death

1

AUTS2

chr7

0.68

23.86

4.64

1.41E-05

2

TAF8

chr6

7.00

28.34

6.58

1.55E-04

3

NAGS

chr17

0.16

10.87

2.58

2.02E-04

4

RP1-130H16.18

chr22

2.88

15.96

3.82

2.23E-04

5

DOCK10

chr2

-1.31

-13.55

3.26

2.38E-04

6

CLEC4E

chr12

0.56

4.53

1.09

2.43E-04

7

APOBR

chr16

0.88

6.59

1.60

2.71E-04

8

LYST

chr1

-5.12

-29.58

7.43

3.86E-04

9

SLC39A11

chr17

0.25

13.82

3.48

3.96E-04

10

RP11-3G21.1

chr8

0.29

6.95

1.78

4.67E-04

11

TIMM13

chr19

-0.38

-22.98

6.48

0.001

12

VCX

chrX

3.39

12.55

3.56

0.001

13

SELPLG

chr12

0.05

6.55

2.08

0.004

Expansion Size

1

CDKL1

chr14

3.06

21.39

4.52

5.28E-05

2

FAM87A

chr8

-0.50

-9.21

2.24

2.94E-04

3

RP11-481 J2.3

chr16

0.64

7.52

2.14

0.001

4

EFCAB14

chr1

-2.38

-34.03

9.98

0.002

Sense RNA Foci

1

CATIP-AS1

chr2

-0.002

-0.10

0.02

6.34E-05

Antisense RNA Foci

1

CCDC127

chr5

0.003

0.16

0.04

0.001

Poly(GP)

1

EEF2K

chr16

-10.11

- 495.81

133.94

9.69E-04

Methylation

1

AC006946.16

chr22

-0.03

-8.14

2.05

4.32E-04

2

RP11-555 M1.3

chr3

0.07

4.18

1.33

0.004

3

A1BG

chr19

-0.009

-8.69

2.78

0.004

Disease Subgroup

1

TMPPE

chr3

0.02

3.03

1.10

0.006

2

EDEM2

chr20

0.93

8.44

3.13

0.007

3

CD37

chr19

-0.39

-6.42

2.41

0.008

4

MZT2B

chr2

-1.15

-22.86

8.75

0.009

5

PLK5

chr19

-0.02

-2.52

1.00

0.01

6

NOTUM

chr17

-0.32

-4.87

2.30

0.03

Variable

Order

Gene

Chr

Coef1

HR

CI

P-value

Survival after Onset

1

SGSM3

chr22

-0.02

0.10

0.04–0.28

1.31E-05

2

EFNA2

chr19

-0.03

0.19

0.07–0.51

0.001